TODAY’S RESEARCH

AAL, ALK, AMZN, ARGX, ARLO, BMRN, BOOT, BWA, CBLK, CE, CELG, CERN, CMCSA, CMG, COLM, COR, CRI, CRS, CY, DLR, EFX, EXPE, FTI, GILD, GOOG, GRUB, HLX, INTC, LEA, LOGM, LSTR, LUV, MEOH, MO, MPWR, NOK, NOV, NTGR, NUVA, ORCL, PFFT, PTC, PTEN, RES, RTN, SAVE, SGEN, SNAP, SNDX, SYK, TRN, TWTR, UNP, VC, VNE, VRSN, WDC, Health Care IT, Video Games, Semiconductor Capital Equipment, WRG Washington Strategy

Today’s Calls & Conferences

Why Do Millennials Embrace the Retail Sharing Economy? Expert Discussion on Key Consumer Drivers

Friday, October 26
10:30 AM ET

Web Registration
Please click on the link below to register for the call and dial in information will be emailed directly to you.

*Please note: If you register POST call start time, an email will NOT be sent with the dial in number, but will appear directly on screen after you hit submit.

http://www.directeventreg.com/registration/event/9387579

Hosted by
Oliver Chen, CFA Cowen’s Retail & Luxury Analyst
Expert Speaker
Kathy Sheehan Executive Vice President and Global Director, GfK Consumer Life

Washington Wrap Up: Trade & Midterms - Latest and Greatest

Friday, October 26
11:00 AM ET

Web Registration
Please click on the link below to register for the call and dial in information will be emailed directly to you.

*Please note: If you register POST call start time, an email will NOT be sent with the dial in number, but will appear directly on screen after you hit submit.

http://www.directeventreg.com/registration/event/2256709

Hosted by Chris Krueger Senior Washington Strategist, Cowen and Company

Drug Pricing: Analyzing Recent White House Proposals

Friday, October 26

Please see addendum of this report for important disclosures.
Web Registration
Please click on the link below to register for the call and dial in information will be emailed directly to you.
‘Please note: If you register POST call start time, an email will NOT be sent with the dial in number, but will appear directly on screen after you hit submit.
http://www.directeventreg.com/registration/event/1859123

Hosted by
Rick Weissenstein, Healthcare Policy Analyst, Cowen and Company

Guest Speaker
Michael McCaughan of Prevision Policy

Today’s Research Highlights

Technology, Media & Telecom

Alphabet
GOOG: Solid 3Q18 Results, But a Touch Light on Top-line

OUTPERFORM (1)

THE COWEN INSIGHT

GOOG reported solid 3Q18 results, but revenue was 1% below our forecast, while Core GOOG margins were slightly below our forecast. Opex and Capex ramp persists, as investments in headcount, prod’n equip., Data Centers, etc. continue behind future growth opportunities. Modest changes to L-T forecast, Price Target remains $1,420, maintain Outperform.

John Blackledge
646 562 1359
john.blackledge@cowen.com

Link to Full Note
Technology, Media & Telecom

Amazon.com

3Q18 Review: Big Margin Beat, N.A Strength Offset by Softer Int'l Revenue

OUTPERFORM (1)
Symbol          NASDAQ: AMZN
Price Target    $2,250.00 (Prior $2,300.00)
Price (10/25/2018) $1,782.17
Market Cap (MM)  $869,237.7

THE COWEN INSIGHT
AMZN’s 3Q18 results were mixed, as Op Inc. (GAAP) was 46% above our forecast, but revenue was 1% lower than expected as NA strength was offset by an Int’l shortfall. 4Q18 rev. guide calls for +11%-21% y/y growth x-FX vs. our/cons. estimates of +21%/+22%, while the high end of Op Inc. guide bracketed our estimate. Our new forecast moves our PT to $2,250/share from $2,300. Maintain Outperform.

John Blackledge
646 562 1359
john.blackledge@cowen.com

Basic Materials

Celanese Corp.

Interesting Stocks and Why You Should Own Them (Vol. 3-CE)

OUTPERFORM (1)
Symbol          NYSE: CE
Price Target    $130.00 (Prior $125.00)
Price (10/25/2018) $96.41
Market Cap (MM)  $12,895.6

THE COWEN INSIGHT
We believe investors may be too narrowly focused on perceived headwinds tied to CE’s auto exposure and the likelihood of an earnings drag from Acetyl Intermediates (AI). We sense that these concerns are overshadowing a strong growth plan, mostly controlled by CE’s own action, which will more than mitigate headwinds. Raising estimates and PT to $130 on improved outlook and execution capability.

Charles Neivert
646 562 1370
charles.neivert@cowen.com

Technology, Media & Telecom

Monolithic Power Systems

Diverse Growth Drivers Holding The Umbrella To Weather The Storm

OUTPERFORM (1)
Symbol          NASDAQ: MPWR
Price Target    $180.00 (Prior $180.00)
Price (10/25/2018) $108.43
Market Cap (MM)  $4,586.6

THE COWEN INSIGHT
Another typically strong MPS quarter - our top SMID-Cap pick. The diversity of growth drivers was in full display as softness in consumer/China was offset by four strong verticals. While many peers cut numbers, MPS continues to demonstrate its organic growth story, justifying a premium valuation. Maintain Outperform; $165 PT.

Matthew D. Ramsay
415 646 7373
matt.ramsay@cowen.com
Other Research Today

Technology, Media & Telecom

**Video Games**

Ordometer 2018: Red Over Black

**THE COWEN INSIGHT**

Our updated Ordometer shows that Take-Two’s *Red Dead Redemption 2* has moved into the lead, passing Activision’s *Call of Duty: Black Ops 4* on the eve of RDR2’s release. EA’s *Battlefield V* continues to track well behind the two leading titles.

Doug Creutz, CFA
415 646 7225
doug.creutz@cowen.com

**Link to Full Note**

Technology, Media & Telecom

**Semiconductor Capital Equipment**

Intel Capex Raised by $0.5B to $15.5B. Net Capital Deployed Up by $1B to $14B

**THE COWEN INSIGHT**

Intel raised its 2018 Capex to $15.5B, up from an estimated $15.0B last quarter. This includes $1.5B of customer prepayments; therefore, the net capital deployed will be $14.0B (+19% Y/Y). Management expects logic spending to grow in 2019 and memory to decline. We model 2019 total capex flat.

Krish Sankar
415 646 7372
krish.sankar@cowen.com

**Link to Full Note**

Consumer

**Alaska Air Group**

2019 Revenue Drivers Laid Out, Now Wait For Cost Expectations

**OUTPERFORM (1)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NYSE: ALK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$80.00 (Prior $84.00)</td>
</tr>
<tr>
<td>Price (10/24/2018)</td>
<td>$61.11</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$7,927.3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EPS $</th>
<th>2017A</th>
<th>2018E</th>
<th>2019E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$6.04</td>
<td>$4.17</td>
<td>$5.30</td>
</tr>
<tr>
<td>Consensus</td>
<td>$6.64</td>
<td>$4.14</td>
<td>$5.83</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

Alaska Air Group continues to execute their plan to slow the company’s capacity growth to drive higher revenue to improve margins and returns. The company discussed its plans to drive $330 MM in incremental revenue in 2019 which could result in their unit revenue outperforming the industry. If management can control costs as they have in the past, 2019 should be a strong year.

Helane Becker
646 562 1399
helane.becker@cowen.com

**Link to Full Note**
Consumer
Altria Group
Leader of the Pack

OUTPERFORM (1)
Symbol NYSE: MO
Price Target $74.00 (Prior $70.00)
Price (10/24/2018) $62.31
Market Cap (MM) $117,465.3

THE COWEN INSIGHT
As was the case a decade ago, MO is again taking a leadership position in the tobacco industry by leaning into regulatory oversight, having proposed limiting characterizing flavors in vapor, while also pulling its pod-based products from the market (impacting 20% of its vapor business). Maintain Outperform.

Vivien Azer
646 562 1351
vivien.azer@cowen.com

Consumer
American Airlines Group
On Track to Deliver Revenue Improvement

OUTPERFORM (1)
Symbol NASDAQ: AAL
Price Target $46.00
Price (10/24/2018) $30.34
Market Cap (MM) $15,116.7

THE COWEN INSIGHT
AAL shares are rated Outperform. The company reported in line 3Q18 results and looking ahead to 4Q18 we believe the company will continue to see positive revenue trends. There are a number of positive initiatives that should drive higher revenues in 2019 and beyond.

Helane Becker
646 562 1399
helane.becker@cowen.com

Health Care
argenx
Efgartigimod Remains Strong in MG, ITP. Well Funded Through 2022.

OUTPERFORM (1)
Symbol NASDAQ: ARGX
Price Target NA
Price (10/25/2018) $74.86
Market Cap (MM) $2,689.4

THE COWEN INSIGHT
ARGX reported 3Q18 financials and provided a pipeline update. ASH will be a significant catalyst for the stock, including a detailed update on ARGX-110 in AML as well as full Ph 2 ITP dataset for efgartigimod. The risk/reward into ASH is favorable for the stock.

Boris Peaker, Ph.D., CFA
646 562 1377
boris.peaker@cowen.com
Technology, Media & Telecom

Arlo Technologies

Q3:18 - Revenue Upside & Strong Subscriber Growth, But Weak Gross Margin Guide

OUTPERFORM (1)

Symbol | NYSE: ARLO
Price Target | $25.00 (Prior $28.00)
Price (10/25/2018) | $14.46
Market Cap (MM) | $1,073.7

<table>
<thead>
<tr>
<th>EPS $</th>
<th>2018E</th>
<th>2019E</th>
<th>2020E</th>
<th>2021E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>(0.29)</td>
<td>(0.51)</td>
<td>0.33</td>
<td>0.90</td>
</tr>
<tr>
<td>Prior</td>
<td>(0.41)</td>
<td>(0.25)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Consensus</td>
<td>(0.41)</td>
<td>(0.19)</td>
<td>0.08</td>
<td>0.86</td>
</tr>
</tbody>
</table>

Robert W. Stone
617 946 3932
rob.stone@cowen.com

THE COWEN INSIGHT

Q3:18 non-GAAP loss/share was 5c vs. St. (19c) on 11% better revenue and much lower Opex. Subscribers grew 105% Y/Y and new Arlo Smart AI features, including audio, were announced. However, a focus on user growth and higher promotional spending lowers expected Q4:18 and H1:19 gross margins ahead of new products next year. We trim our PT to $25 (vs. $28), based on EV/Sales sum-of-the-parts.

Health Care

BioMarin Pharmaceutical

Reports Q3; Palynziq Off To An Encouraging Start

OUTPERFORM (1)

Symbol | NASDAQ: BMRN
Price Target | $150.00
Price (10/25/2018) | $96.43
Market Cap (MM) | $17,125.0

<table>
<thead>
<tr>
<th>EPS $</th>
<th>2017A</th>
<th>2018E</th>
<th>2019E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$0.43</td>
<td>$0.70</td>
<td>$0.95</td>
</tr>
<tr>
<td>Prior</td>
<td>-</td>
<td>$0.60</td>
<td>$1.25</td>
</tr>
<tr>
<td>Consensus</td>
<td>-</td>
<td>$(0.72)</td>
<td>$0.14</td>
</tr>
</tbody>
</table>

Phil Nadeau, Ph.D.
646 562 1336
phil.nadeau@cowen.com

THE COWEN INSIGHT

BMRN reported Q3 revenue of $392MM, above consensus $358MM, aided by ex-U.S. orders for Naglazyme. Palynziq’s launch is off to a solid start with 124 patients on commercial drug at the end of Q3, with 250-300 patients anticipated by YE. We continue to think that BioMarin is a core mid-cap holding.

Consumer

Boot Barn Holdings

Biggest BOOT Brand In The Industry Getting Bigger. Reit Outperform

OUTPERFORM (1)

Symbol | NYSE: BOOT
Price Target | $33.00 (Prior $31.00)
Price (10/25/2018) | $28.16
Market Cap (MM) | $788.4

<table>
<thead>
<tr>
<th>EPS $</th>
<th>2018A</th>
<th>2019E</th>
<th>2020E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$0.71</td>
<td>$1.25</td>
<td>$1.43</td>
</tr>
<tr>
<td>Prior</td>
<td>-</td>
<td>$1.16</td>
<td>$1.38</td>
</tr>
<tr>
<td>Consensus</td>
<td>$0.69</td>
<td>$1.13</td>
<td>$1.35</td>
</tr>
</tbody>
</table>

Oliver Chen, CFA
646 562 1424
oliver.chen@cowen.com

THE COWEN INSIGHT

2Q19 Comps Exceed Expectations & Quarter-To-Date Momentum Continues: BOOT’s 2Q Comps of +11.3% were above Cowen’s heightened expectations and quarter to date are trending above 2Q results. Gross margin expansion was above expectations as private brand penetration growth remains robust. FY19 guide raised +10% at mid-point but 3Q trails Street.
Capital Goods/Industrials

**BorgWarner**

Organic Growth More than Offsets Tough Production Atmosphere

**OUTPERFORM (1)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NYSE: BWA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$46.00</td>
</tr>
<tr>
<td>Price (10/25/2018)</td>
<td>$37.72</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$7,856.1</td>
</tr>
</tbody>
</table>

**EPS $**

<table>
<thead>
<tr>
<th></th>
<th>2017A</th>
<th>2018E</th>
<th>2019E</th>
<th>2020E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$3.88</td>
<td>$4.35</td>
<td>$4.65</td>
<td>$5.08</td>
</tr>
<tr>
<td>Prior</td>
<td>-</td>
<td>$4.34</td>
<td>$4.67</td>
<td>$5.05</td>
</tr>
<tr>
<td>Consensus</td>
<td>-</td>
<td>$4.38</td>
<td>$4.72</td>
<td>$5.20</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

BorgWarner reported results that were better than our expectations coming out of the September Analyst Day, reporting organic growth despite a tough macro backdrop. We believe that the challenges facing BWA and auotech peers likely linger into 1H19, but believe the valuation remains attractive given the company’s improving position in electrification and the long term growth trajectory.

Jeffrey Osborne  
646 562 1391  
jeffrey.osborne@cowen.com

---

Technology, Media & Telecom

**Carbon Black**

Solid 3Q Results

**OUTPERFORM (1)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NASDAQ: CBLK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$24.00 (Prior $28.00)</td>
</tr>
<tr>
<td>Price (10/25/2018)</td>
<td>$16.50</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$1,229.8</td>
</tr>
</tbody>
</table>

**EPS $**

<table>
<thead>
<tr>
<th></th>
<th>2017A</th>
<th>2018E</th>
<th>2019E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$4(0.5)</td>
<td>$(1.19)</td>
<td>$(0.64)</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

CBLK reported a solid quarter, led by healthy ARR growth of 31% y/y and strong cloud revenue growth of >125% y/y. The co. also raised 2018 guidance. However, short-term billings growth, while a healthy 25% y/y, was slightly below consensus. We believe the AH sell-off (down 8-9%) is overdone and maintain that CBLK is very well positioned to take share in the endpoint security market.

Gregg Moskowitz, CFA  
646 562 1390  
gregg.moskowitz@cowen.com

---

Capital Goods/Industrials

**Carpenter Technology Corporation**

Resetting F19 Ests.

**OUTPERFORM (1)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NYSE: CRS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$53.00 (Prior $66.00)</td>
</tr>
<tr>
<td>Price (10/24/2018)</td>
<td>$44.61</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$2,110.8</td>
</tr>
</tbody>
</table>

**EPS $**

<table>
<thead>
<tr>
<th></th>
<th>2017A</th>
<th>2018A</th>
<th>2019E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$1.08</td>
<td>$2.50</td>
<td>$3.13</td>
</tr>
<tr>
<td>Prior</td>
<td>-</td>
<td>$2.52</td>
<td>$3.52</td>
</tr>
<tr>
<td>Consensus</td>
<td>$1.08</td>
<td>$2.50</td>
<td>$3.29</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

We pared our F19E EPS for Q1’s slower start, the LPW acquisition, and a slower volume phase in at the Athens facility. Our new PT is $53, 9x F19E EV/EBITDA.

Gautam Khanna  
617 946 3978  
gautam.khanna@cowen.com
Consumer

**Carter’s**

We Remain Cautious On Sell Side Estimates Into Next Year

**THE COWEN INSIGHT**

The Carter’s brand ranks near the top of our surveys within baby and young kids but our model remains far below consensus estimates and we are cutting our price target to $85, 9x FY19E EV/EBITDA - in line with sector average. Tariffs create incremental risk.

John Kernan, CFA
646 562 1324
john.kernan@cowen.com

Health Care

**Celgene**

Quarterly Financials Solid; 5 Product Launches Expected Through 2020

**THE COWEN INSIGHT**

CELG reported Q3 financials above consensus driven largely by sales/inventory buildup for Otezla and Abraxane. Yearly guidance for Otezla and Total Revenue was bumped up. Celgene and partners will have several presentations across the portfolio at ASH and management expects to launch five products through 2020. With shares trading at <7X 2019E EPS, we continue to think CELG is undervalued.

Phil Nadeau, Ph.D.
646 562 1336
phil.nadeau@cowen.com

Health Care

**Cerner Corporation**

3Q18 Results Largely In-Line, But 2018 Adj. EPS Expected At Low-End Of Range

**THE COWEN INSIGHT**

CERN reported adj. EPS of $0.63, up +3.5% y/y and inline. Revs of $1.34B, +5% y/y were slightly below consensus ($1.36B). Bookings of $1.59B beat consensus of $1.55B although licensed s/w bookings were below expectations (-3%). Mgmt guiding investors to low-end of 2018 adj. EPS range due to lower s/w bookings raises some N-T concerns as CERN looks to transition to more tech-enabled services model.

Charles Rhyee
646 562 1376
charles.rhyee@cowen.com
### Consumer

#### Chipotle Mexican Grill

**A Niccol For Our Thoughts**

**MARKET PERFORM (2)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NYSE: CMG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$430.00</td>
</tr>
<tr>
<td>Price (10/25/2018)</td>
<td>$423.88</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$11,785.6</td>
</tr>
</tbody>
</table>

#### EPS $ 2017A 2018E 2019E

<table>
<thead>
<tr>
<th></th>
<th>2017A</th>
<th>2018E</th>
<th>2019E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$5.96</td>
<td>$8.50</td>
<td>$11.53</td>
</tr>
<tr>
<td>Prior</td>
<td>-</td>
<td>$8.68</td>
<td>$11.68</td>
</tr>
<tr>
<td>Consensus</td>
<td>$5.96</td>
<td>$9.17</td>
<td>$11.56</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

Sales improved in October following the 3Q comp miss, though we note underlying sales trends in October are only back to levels experienced in 1H18. We maintain our 2019-20E comp estimate of 4.5% and highlight two-year trends need to accelerate in order for the company to deliver against consensus same store sales forecasts.

Andrew M. Charles, CFA
646 562 1332
andrew.charles@cowen.com

[Link to Full Note](#)

---

### Consumer

#### Columbia Sportswear

**Initial Guidance For FY19 Indicates Confidence**

**OUTPERFORM (1)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NASDAQ: COLM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$103.00</td>
</tr>
<tr>
<td>Price (10/25/2018)</td>
<td>$87.70</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$6,135.6</td>
</tr>
</tbody>
</table>

#### EPS 2017A 2018E 2019E

<table>
<thead>
<tr>
<th></th>
<th>2017A</th>
<th>2018E</th>
<th>2019E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$2.91</td>
<td>$3.61</td>
<td>$4.16</td>
</tr>
<tr>
<td>Prior</td>
<td>-</td>
<td>$3.59</td>
<td>$4.15</td>
</tr>
<tr>
<td>Consensus</td>
<td>$2.91</td>
<td>$3.48</td>
<td>$3.90</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

We continue to see potential for more estimate revisions on the strength of sales and gross margin. Reiterate $103 price target and view momentum within the Columbia and Sorel brands as upside drivers.

John Kernan, CFA
646 562 1324
john.kernan@cowen.com

[Link to Full Note](#)

---

### Technology, Media & Telecom

#### Comcast Corp.

**Cable Momentum Continues; The Narrative Shifts to Sky Execution**

**MARKET PERFORM (2)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NASDAQ: CMCSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$41.00 (Prior $40.00)</td>
</tr>
<tr>
<td>Price (10/25/2018)</td>
<td>$35.84</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$163,054.3</td>
</tr>
</tbody>
</table>

#### EBITDA_ADJ 2017A 2018E 2019E

<table>
<thead>
<tr>
<th></th>
<th>2017A</th>
<th>2018E</th>
<th>2019E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$27,957.0</td>
<td>$29,237.7</td>
<td>$30,388.4</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

Comcast posted good 3Q18 results including upside Cable video and HSI sub metrics, and Broadcast and Film slightly worse, but no major surprises. Fundamentals remain intact, and perhaps incrementally better for Cable, but with PF net leverage at 3.5x and paying~14.6x for a Satellite/Media company, we believe stock appreciation is limited until proof points emerge around execution on Sky.

Gregory Williams, CFA
646 562 1367
gregory.williams@cowen.com

[Link to Full Note](#)
Technology, Media & Telecom
CoreSite Realty Corp.
Disappointing Preliminary 2019 Outlook; Growth Expected To Further Decelerate

MARKET PERFORM (2)
Symbol NYSE: COR
Price Target $104.00 (Prior $107.00)
Price (10/25/2018) $100.36
Market Cap (MM) $4,836.2

THE COWEN INSIGHT
COR reported solid 3Q18 headline results including rev/EBITDA/FFO above St. estimates although leasing of $6.1MM was weak vs. its TTM avg. of $8.7MM. The company also provided disappointing 2019 guidance including growth that is expected to further decelerate vs. 2018 and below previous Street estimates and we think could still prove aggressive. Maintain Market Perform.

Colby Synesael
646 562 1355
colby.synesael@cowen.com

Technology, Media & Telecom
Cypress Semiconductor
Not Great, But Decent - All Things Considered

OUTPERFORM (1)
Symbol NASDAQ: CY
Price Target $18.00
Price (10/25/2018) $12.10
Market Cap (MM) $4,372.8

THE COWEN INSIGHT
CY is not immune to the demand challenges affecting other semis, and a guide down was not unexpected. Autos remain an ongoing concern of ours, but CY has remained astute in managing working capital and GMs still have a lot of headroom - a rarity in semis. We maintain our $18 target.

Karl Ackerman, CFA
415 646 7219
karl.ackerman@cowen.com

Technology, Media & Telecom
Digital Realty Trust
In-Line 3Q18 Results; Strong Leasing

OUTPERFORM (1)
Symbol NYSE: DLR
Price Target $125.00 (Prior $130.00)
Price (10/25/2018) $116.80
Market Cap (MM) $27,017.3

THE COWEN INSIGHT
DLR reported largely in-line results with strong leasing of $69.2MM vs. its TTM avg. of $67.2MM. While Ascenty and new lease accounting standards create noise in the model, fundamentals continue to be strong heading into 2019. We continue to believe DLR is well positioned as a quality name to own in an increasingly risk-off environment. Reiterate Outperform.

Colby Synesael
646 562 1355
colby.synesael@cowen.com
Technology, Media & Telecom

**Equifax**

EFX 3Q18 Follow Up: Show Me Story

**OUTPERFORM (1)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NYSE: EFX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$122.00 (Prior $141.00)</td>
</tr>
<tr>
<td>Price (10/25/2018)</td>
<td>$98.31</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$11,837.7</td>
</tr>
<tr>
<td><strong>EPS $</strong></td>
<td><strong>2018E</strong></td>
</tr>
<tr>
<td>Cowen</td>
<td>$5.73</td>
</tr>
<tr>
<td>Consensus</td>
<td>$5.85</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

EFX shares traded down -15% post disappointing 3Q results. We do not believe the shares merit trading at post breach levels and expect a near-term bounce. That said EFX has become a show me story. We see two catalysts to get the stock going - reinstating long-term growth targets and sizing the potential litigation/regulatory liability. We now expect the revenue acceleration to take hold in 2019E.

George Mihalos  
646 562 1360  
george.mihalos@cowen.com

Technology, Media & Telecom

**Expedia Group**

Q3: Core Nights +11%, Solid EBITDA; PT Up To $145

**OUTPERFORM (1)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NASDAQ: EXPE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$145.00 (Prior $135.00)</td>
</tr>
<tr>
<td>Price (10/25/2018)</td>
<td>$117.57</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$17,571.0</td>
</tr>
<tr>
<td><strong>EBITDA $</strong></td>
<td><strong>2017A</strong></td>
</tr>
<tr>
<td>Cowen</td>
<td>$1,712.0</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

On a backdrop of investor concern, due in part to unreliable third party data, EXPE Q3 nights were +13% (11% core), in line with our est. (but 100 bps below 1H), and EBITDA was strong across segments on ad ROI & lower costs, despite weaker hotel take rates. While Q4E EBITDA guide is lower, we leave our 18-20E annual est. unchanged. PT to $145 (vs $135) as we move Sum Of Parts to 20E.

Kevin Kopelman, CFA  
646 562 1348  
kevin.kopelman@cowen.com

Health Care

**Gilead Sciences**

A Top- And Bottom- Line Beat With A Modest Raise To 2018 Guidance

**OUTPERFORM (1)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NASDAQ: GILD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$85.00</td>
</tr>
<tr>
<td>Price (10/25/2018)</td>
<td>$68.62</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$88,954.9</td>
</tr>
<tr>
<td><strong>EPS $</strong></td>
<td><strong>2017A</strong></td>
</tr>
<tr>
<td>Cowen</td>
<td>$8.84</td>
</tr>
<tr>
<td>Prior</td>
<td>-</td>
</tr>
<tr>
<td>Consensus</td>
<td>$8.84</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

Q3 total rev. ($5.60B vs. $5.38B) and non-GAAP EPS ($1.84 vs $1.63) were ahead of consensus. HIV and HCV revenue were more or less in-line, with revenue upside coming from Letairis. Gilead’s HIV franchise continues to perform, and Biktarvy’s launch is on pace to be the best yet. We are hopeful that Gilead’s trough earnings have passed. We remain at Outperform and our $85 price target is unchanged.

Phil Nadeau, Ph.D.  
646 562 1336  
phil.nadeau@cowen.com

Link to Full Note
Technology, Media & Telecom

GrubHub

3Q18 Earnings Reaction: Market Expansion Ambitions Come At A Cost

THE COWEN INSIGHT
Shares dropped 12% in trading yesterday as an EBITDA miss and low 4Q Guidance offset favorable GFS and Order growth. GRUB is now targeting 200 new markets in 2018, 2x the original goal. The investment makes sense long-term but comes at a near-term cost and impacts 2019 EBITDA. Reiterate Outperform, but lower Target Price to $122 from $160.

Thomas Champion
646 562 1365
thomas.champion@cowen.com

Health Care

Health Care IT

Takeaways From 7th Annual Rock Health Summit

THE COWEN INSIGHT
We recently attended the Rock Health Summit, a digital health focused industry conference. Themes from the Summit align with our beliefs that healthcare is moving to an integrated care model with technology playing a key role. While speakers were positive on the opportunity, there was recognition that digital players need to work within the existing system and that change will take time.

Charles Rhyee
646 562 1376
charles.rhyee@cowen.com

Energy

Helix Energy Solutions Group

Strong 3Q Lightens the 4Q Load - 3Q18 Earnings Recap

THE COWEN INSIGHT
HLX o/p the OIH by ~20bp after a 3Q beat. The 3Q EBITDA beat further de-risks the narrowed 2018 EBITDA guidance range. While we believe HLX’s well intervention markets are trending favorably our ’19/20 estimates are modestly lower owing to a more cautious Production assumption.

Marc Bianchi, CFA
646 562 1393
marc.bianchi@cowen.com
Technology, Media & Telecom

Intel
Stellar Results, But Multiple Concerns Remain Into 2019

THE COWEN INSIGHT
Intel posted another impressive beat/raise. A notably strong 3Q PC and datacenter market put Intel’s 2018 on pace for its first year of double-digit growth since 2011. Despite this, we see a precarious set-up heading into 2019 given difficult comps, macro headwinds, manufacturing questions and renewed competition from AMD. Estimates higher, valuation compresses further. Market Perform; PT to $50.

Matthew D. Ramsay
415 646 7373
matt.ramsay@cowen.com

Landstar System
Another Record Quarter for Landstar

THE COWEN INSIGHT
LSTR reported a record 3Q, with EPS beating our estimate and the street’s. New agent hires are contributing at record rates and ’18 organic revenue growth of $1bn is in sight. We are raising our EPS estimates and price target but maintaining our Market Perform rating as we seek more clarity on the state of the freight environment heading into LSTR’s mid-November and December peak season and ’19.

Jason H. Seidl
646 562 1404
jason.seidl@cowen.com

LEAR Corporation
Lowers Outlook But Leverage Apparent in 2H19; E-Systems Continues to Shine

THE COWEN INSIGHT
Low production volumes resulted in weak 3Q results. While management lowered full year guidance and expects tailwinds in 2019, the company was upbeat on quoting activity, with E-systems growing faster than seating. We see the VC initiative as a positive step toward fostering additional M&A in the E-Systems business and continue to see Lear as a compelling value play in auto tech.
Technology, Media & Telecom

LogMeIn

Strong 3Q Rebound; Expect Ongoing Improvement

OUTPERFORM (1)

Symbol | NASDAQ: LOGM
Price Target | $115.00
Price (10/25/2018) | $75.84
Market Cap (MM) | $3,933.7

Revenue $ | 2017A | 2018E | 2019E
Cowen | $1,024.1 | $1,203.3 | $1,255.9

THE COWEN INSIGHT

LOGM reported an impressive 3Q rebound, with revenue and EPS well above Street estimates, and much better renewal rates in its Collaboration segment. We continue to see several other catalysts that should help to drive stock outperformance going forward, and reiterate LOGM as one of our top picks.

Gregg Moskowitz, CFA
646 562 1390
gregg.moskowitz@cowen.com

Link to Full Note

Basic Materials

Methanex Corp.

3Q18 Results and 4Q18 Guidance Roughly In Line; Maintain Outperform and $89 PT

OUTPERFORM (1)

Symbol | NASDAQ: MEOH
Price Target | $89.00
Price (10/25/2018) | $63.69
Market Cap (MM) | $4,971.2

EPS $ | 2018E | 2019E | 2020E
Cowen | $7.81 | $9.07 | $10.31
Prior | $7.87 | $9.08 | $10.49
Consensus | $7.36 | $6.26 | $7.23

THE COWEN INSIGHT

We are updating our model to reflect most recent results and outlook. We believe MEOH shares represent one of the better values in our chemical universe as we see pricing remaining healthy through 2020. Maintain Outperform and $89 PT.

Charles Neivert
646 562 1370
charles.neivert@cowen.com

Link to Full Note

Energy

National Oilwell Varco

3Q18 Earnings at a Glance

MARKET PERFORM (2)

Symbol | NYSE: NOV
Price Target | $45.00
Price (10/25/2018) | $37.01
Market Cap (MM) | $14,160.8

THE COWEN INSIGHT

Negative: Somewhat expected EBITDA miss, driven by Wellbore and CAPS partly offset by lower corporate expense. Cost pressure in Wellbore and slowing NAms create risk to 4Q which consensus has modeled up $25MM from 3Q. The company will give guidance on the 11AM call. Beyond the 4Q outlook, anticipation of NOV’s upcoming analyst day will remain a focus for investors.

Marc Bianchi, CFA
646 562 1393
marc.bianchi@cowen.com

Link to Full Note
Technology, Media & Telecom

**Netgear**

**Q3:18 Upside on Higher Sales & Gross Margin; Tariffs Don’t Change 2019 Targets**

**MARKET PERFORM (2)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NASDAQ: NTGR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$63.00</td>
</tr>
<tr>
<td>Price (10/25/2018)</td>
<td>$6.21</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>1,853.5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EPS</th>
<th>2018E</th>
<th>2019E</th>
<th>2020E</th>
<th>2021E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$2.09</td>
<td>$2.66</td>
<td>$2.95</td>
<td>$3.16</td>
</tr>
<tr>
<td>Consensus</td>
<td>$2.11</td>
<td>$2.59</td>
<td>$3.15</td>
<td>-</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

Q3:18 non-GAAP EPS were 76c vs. St. 47c, on ~3% higher sales and ~10% higher gross profit. Q4 revenue guidance brackets Consensus, but Op. margins are below on ARLO spin-dis-synergies. NTGR is moving production out of China and will raise prices selectively to offset tariffs and hit 2019 targets. We don’t expect material services contribution yet, maintain Market Perform (2) on modest growth.

Robert W. Stone
617 946 3932
rob.stone@cowen.com

Link to Full Note

---

Technology, Media & Telecom

**Nokia (ADR)**

**3Q18: SOLID OPER RESULTS AND OUTLOOK**

**MARKET PERFORM (2)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NYSE: NOK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$6.00</td>
</tr>
<tr>
<td>Price (10/25/2018)</td>
<td>$5.32</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$29,981.1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EPS $</th>
<th>2018E</th>
<th>2019E</th>
<th>2020E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$0.27</td>
<td>$0.38</td>
<td>$0.47</td>
</tr>
<tr>
<td>Prior</td>
<td>$0.26</td>
<td>$0.35</td>
<td>$0.41</td>
</tr>
<tr>
<td>Consensus</td>
<td>$0.26</td>
<td>$0.36</td>
<td>$0.44</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

NOK delivered solid 3Q18 results and reiterated 2020 margin and EPS targets. At the same time, attaining the mid-point of its CY18 target model requires a significant 4Q18 step-up and NOK announced new strategic actions, including an incremental cost reduction program, to attain its 2020 targets. We have modestly adjusted our oper forecasts with $6 Price Target and Market Perform rating unchanged.

Paul Silverstein
646 562 1340
paul.silverstein@cowen.com

Link to Full Note

---

Health Care

**NuVasive**

**Nu Beginning: CEO Change Shouldn’t Cloud Favorable 3Q Setup**

**OUTPERFORM (1)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NASDAQ: NUVA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$80.00</td>
</tr>
<tr>
<td>Price (10/24/2018)</td>
<td>$62.73</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$3,225.7</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EPS $</th>
<th>2017A</th>
<th>2018E</th>
<th>2019E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$1.89</td>
<td>$2.37</td>
<td>$2.70</td>
</tr>
<tr>
<td>Consensus</td>
<td>$1.91</td>
<td>$2.38</td>
<td>$2.73</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

NUVA shares sold off on the news that Greg Lucier will step down as CEO, to be replaced by Chris Barry, formerly president of MDT’s Surgical Innovations division. Some investors interpreted the move as a sign that NUVA’s 3Q performance was likely subpar, a conclusion we don’t share. We still think the 2H’18 setup is attractive enough to warrant staying positive on the name. Our target remains $80.

Joshua Jennings, M.D.
646 562 1333
josh.jennings@cowen.com

Link to Full Note
**Technology, Media & Telecom**

**Oracle**

**Takeaways From Analyst Day; Gen 2 Seen As a Major Catalyst for ORCL Cloud**

**THE COWEN INSIGHT**

ORCL is focused on two big plays: Cloud ERP and Cloud Database + Cloud Infrastructure. In Cloud ERP, NetSuite is re-accelerating and mgmt sees more existing customers migrating to Fusion. In Cloud Database, Autonomous D/B was released this year and the rollout of Gen 2 Data Centers is perceived as a major leap in IaaS. It remains a show-me story but catalysts are developing. Maintain $56 PT.

J. Derrick Wood, CFA
415 646 7370
derrick.wood@cowen.com

**Energy**

**Patterson-UTI Energy**

**Pumping Prudence - 3Q18 Earnings Recap**

**THE COWEN INSIGHT**

PTEN outperformed the OIH by ~800bps following a 3Q beat and guidance, particularly for Pressure Pumping, that was better than feared. Guidance for the Drilling business was also solid and leading edge rates continue to move higher. 2019 CapEx was not provided and remains a focus for investors. We maintain our Outperform rating and $27 price target.

Marc Bianchi, CFA
646 562 1393
marc.bianchi@cowen.com

**Technology, Media & Telecom**

**Proofpoint**

**Reports 3Q Earnings**

**THE COWEN INSIGHT**

Our caution on PFPT ahead of the 3Q print was justified. While billings growth of 33% y/y slightly exceeded Street ests., short-term billings growth decelerated, initial 2019 guidance was even lower than we had feared, and the co. announced some mgmt changes. While PFPT will still grow at a healthy rate in 2019 (and likely beyond), Street expectations need to be reset. PT to $95 vs. $112 prior.

Gregg Moskowitz, CFA
646 562 1390
gregg.moskowitz@cowen.com
Technology, Media & Telecom

**PTC**

**Solid Overall F4Q Execution; Subscription Model Continues to Accelerate**

**THE COWEN INSIGHT**

PTC posted solid F4Q results on Wednesday, with an accelerating subscription model clearly evident. Initial FY19 guidance was lower than expected in part due to a slightly higher tax rate that will now come into effect, however the longer-term implications of a higher subscription mix are clearly positive, and we would be buyers on any lingering dip.

Matthew Broome, CFA
646 562 1339
matthew.broome@cowen.com

---

Capital Goods/Industrials

**Raytheon**

**Growth Story On Track**

**THE COWEN INSIGHT**

Healthy Q3 results & bookings are driving hikes in the 2018-20 sales & EPS prospects with potential to remain in beat & raise mode for some time; and the stock has support from a 6% 2019 cash flow yield.

Cai von Rumohr, CFA
617 946 3942
cai.von-rumohr@cowen.com

---

Energy

**RPC**

**Fighting the White Space - 3Q18 Earnings Recap**

**THE COWEN INSIGHT**

RES underperformed the OIH by 160 bps after a 3Q EBITDA miss and 4Q guide 20-25% below consensus. The outlook for pressure pumping remains biased lower and our estimates move down 15-20% coming off a lower 4Q18 base. Maintain Market Perform, reduce price target to $12 from $15.

Marc Bianchi, CFA
646 562 1393
marc.bianchi@cowen.com
Health Care

**Seattle Genetics**

**Adcetris Misses Guidance, Focus Now On E2 At ASH.**

**MARKET PERFORM (2)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NASDAQ: SGEN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$71.00 (Prior $82.00)</td>
</tr>
<tr>
<td>Price (10/25/2018)</td>
<td>$65.35</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$10,377.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EPS $</th>
<th>2017A</th>
<th>2018E</th>
<th>2019E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$(0.88)</td>
<td>$(1.19)</td>
<td>$(0.24)</td>
</tr>
<tr>
<td>Prior</td>
<td>-</td>
<td>$(0.79)</td>
<td>$0.10</td>
</tr>
<tr>
<td>Consensus</td>
<td>$(0.88)</td>
<td>$(0.78)</td>
<td>$(0.31)</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

SGEN reported Adcetris sales of $127MM, below consensus of $135MM and company guidance of $130-135MM. Management indicated that the frontline HL launch requires more promotion to displace a 40-year old therapy. E2 data to support sBLA submission in Nov’18, investor focus is now on full E2 data at ASH in Dec’18. Reducing price target to $71.

Boris Peaker, Ph.D., CFA  
646 562 1377  
boris.peaker@cowen.com

[Link to Full Note]

---

Technology, Media & Telecom

**Snap**

**3Q18 Results Mixed as Negative 4Q DAU Comments Overshadow Solid Quarter**

**UNDERPERFORM (3)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NYSE: SNAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$6.00</td>
</tr>
<tr>
<td>Price (10/25/2018)</td>
<td>$6.99</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$8,928.7</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

SNAP posted solid 3Q18 results, as revenue, EBITDA and DAUs were better than expected, but 4Q18 revenue & DAU guide was soft. 3Q18 Rev. growth was 6%/5% better than our/consensus estimates, while DAU declines were better than expected. We tweaked ’18-23 forecast modestly, PT unchanged at $6/share, maintain Underperform.

John Blackledge  
646 562 1359  
john.blackledge@cowen.com

[Link to Full Note]

---

Consumer

**Southwest Airlines Co.**

**Higher Cost Outlook Offsets Revenue Improvement**

**OUTPERFORM (1)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NYSE: LUV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$65.00 (Prior $68.00)</td>
</tr>
<tr>
<td>Price (10/25/2018)</td>
<td>$49.91</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$28,398.8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EPS $</th>
<th>2017A</th>
<th>2018E</th>
<th>2019E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$3.51</td>
<td>$4.11</td>
<td>$4.65</td>
</tr>
<tr>
<td>Consensus</td>
<td>-</td>
<td>$4.13</td>
<td>$4.96</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

Southwest Airlines reported mostly in line 3Q18 results, and issued a 4Q18 outlook that was mostly in line with expectations. The shares were down ~9% owing to the 2019 cost outlook which was disappointing. We believe this pullback is a buying opportunity as the company should continue to see revenue improvements.

Helane Becker  
646 562 1399  
helane.becker@cowen.com

[Link to Full Note]
Consumer

**Spirit Airlines**
Favorable Revenue Outlook

**THE COWEN INSIGHT**
Spirit continues to drive revenue growth through its focus on ancillaries, network tweaks and inventory management. Spirit intends to continue to focus on its operations, including to grow its international operations. Management sees improving asset utilization as an opportunity to drive higher revenue.

<table>
<thead>
<tr>
<th>MARKET PERFORM (2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symbol</td>
</tr>
<tr>
<td>Price Target</td>
</tr>
<tr>
<td>Price (10/25/2018)</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EPS $</th>
<th>2017A</th>
<th>2018E</th>
<th>2019E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$3.25</td>
<td>$3.72</td>
<td>$4.40</td>
</tr>
<tr>
<td>Consensus</td>
<td>-</td>
<td>$3.51</td>
<td>$4.30</td>
</tr>
</tbody>
</table>

Helane Becker
646 562 1399
helane.becker@cowen.com

Health Care

**Stryker Corp.**
SYK Growth Engine Continues To Deliver

**THE COWEN INSIGHT**
SYK posted another quarter of above-consensus revenue and earnings growth with an accompanying FY18 guidance raise. Despite our optimism heading into 4Q and FY19, we recognize the reality of heightened expectations for companies reporting across med devices (and the market broadly). However, another beat and raise is worthy of positive stock momentum relative to peers. Reiterate Outperform.

<table>
<thead>
<tr>
<th>OUTPERFORM (1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symbol</td>
</tr>
<tr>
<td>Price Target</td>
</tr>
<tr>
<td>Price (10/25/2018)</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EPS $</th>
<th>2017A</th>
<th>2018E</th>
<th>2019E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$6.49</td>
<td>$7.25</td>
<td>$8.00</td>
</tr>
<tr>
<td>Consensus</td>
<td>$6.49</td>
<td>$7.25</td>
<td>$7.94</td>
</tr>
</tbody>
</table>

Joshua Jennings, M.D.
646 562 1333
josh.jennings@cowen.com

Health Care

**Syndax Pharmaceuticals**
E2112 PFS Negative, OS Possible. Advancing Entinostat Combo In NSCLC.

**THE COWEN INSIGHT**
With P3 E2112 now fully enrolled, the negative PFS result is disappointing, though not entirely surprising. OS remains possible (recall OS positive in P2; E2112 design favors potential OS benefit). SNDX is positioned for a relatively high-risk/reward opportunity, committing to a proposed pivotal trial of entinostat+pembro in NSCLC, which hinges on validation of a peripheral monocyte biomarker.

<table>
<thead>
<tr>
<th>OUTPERFORM (1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symbol</td>
</tr>
<tr>
<td>Price Target</td>
</tr>
<tr>
<td>Price (10/25/2018)</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EPS $</th>
<th>2017A</th>
<th>2018E</th>
<th>2019E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$(2.90)</td>
<td>$(3.05)</td>
<td>$(3.36)</td>
</tr>
<tr>
<td>Consensus</td>
<td>$(2.88)</td>
<td>$(3.15)</td>
<td>$(3.67)</td>
</tr>
</tbody>
</table>

Chris Shibutani, M.D.
617 946 3733
chris.shibutani@cowen.com
Energy
TechnipFMC
Waiting for 2019 Guidance - 3Q18 Earnings Recap

OUTPERFORM (1)
Symbol NYSE: FTI
Price Target $37.00
Price (10/25/2018) $27.02
Market Cap (MM) $12,280.6

THE COWEN INSIGHT
FTI u/p the OIH by 220bps as unchanged Subsea guidance implies lower 4Q and 2018 exit margin, and absence of 2019 guide leaves investors fearing the worst. Orders were solid and management continues to see good prospects, our estimates move higher on strong orders. Cash flow was improved, but still low relative to EBITDA.

Marc Bianchi, CFA
646 562 1393
marc.bianchi@cowen.com

Capital Goods/Industrials
Trinity Industries
Opaque Guidance Stokes Unnecessary Fear; Story Compelling

OUTPERFORM (1)
Symbol NYSE: TRN
Price Target $47.00
Price (10/24/2018) $33.54
Market Cap (MM) $4,913.6

THE COWEN INSIGHT
TRN provided a 2019 EPS range but not much guidance on many key variables post spin, fueling uncertainty and leaving investors concerned about rail manufacturing margins, among other things. We continue to believe margins will improve on higher production and better mix. Additionally, TRN materially beat its initial annual guidance in the last three years and is on track to do the same in 2018.

Matt Elkott
646 562 1409
matthew.elkott@cowen.com

Technology, Media & Telecom
Twitter
TWTR: 3Q18 Results - Upside Led by Accelerating US Advertising Growth

UNDERPERFORM (3)
Symbol NYSE: TWTR
Price Target $27.00 (Prior $24.00)
Price (10/24/2018) $27.54
Market Cap (MM) $20,871.1

THE COWEN INSIGHT
TWTR’s 3Q18 results were strong, as revenue & EBITDA were +9% & +26% above our estimates led by accelerating US adv. growth. MAU declines of 9MM were worse than guide of 4-6MM loss, but DAU growth of +9% y/y vs. +11% in 2Q18 remained solid. TWTR’s 4Q18 guide was also better than expected, as such we raised our ’18-’23 forecast. Price Target to $27 from $24, maintain Underperform.

John Blackledge
646 562 1359
john.blackledge@cowen.com
Capital Goods/Industrials

**Union Pacific Corp.**

Unified Plan 2020 Showing Some Early Promise

**THE COWEN INSIGHT**

Results were solid and included a record quarterly EPS. Pricing remains somewhat below peers. Service is suboptimal, but new operating plan is showing early signs of success. We're raising our '19 EPS estimate and PT modestly but maintaining our Market Perform while we monitor the new plan and as the upside reflected in our price target is not compelling enough.

**MARKET PERFORM (2)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NYSE: UNP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$153.00 (Prior $151.00)</td>
</tr>
<tr>
<td>Price (10/25/2018)</td>
<td>$144.15</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$106,208.3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$(5.79)</td>
<td>$7.85</td>
<td>$9.00</td>
<td></td>
</tr>
<tr>
<td>Consensus</td>
<td>$(5.79)</td>
<td>$7.64</td>
<td>$8.63</td>
<td></td>
</tr>
</tbody>
</table>

Jason H. Seidl  
646 562 1404  
jason.seidl@cowen.com

---

Capital Goods/Industrials

**Veoneer**

Slower Ramp & Higher R&D Investment in 2019 Push Profitability Beyond 2020

**THE COWEN INSIGHT**

Global automotive weakness has caused some OEMs to delay production starts and slow some production ramps. This has lead management to reduce its confidence in the company's 2020 sales target of $3bn. Active Safety order intake has remained strong and the company is sharply increasing its R&D spend to support the effort. This has caused profitability to shift out beyond 2020 in our view.

**MARKET PERFORM (2)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NYSE: VNE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$30.00 (Prior $34.00)</td>
</tr>
<tr>
<td>Price (10/25/2018)</td>
<td>$31.88</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$2,778.9</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$(2.92)</td>
<td>$(2.98)</td>
<td>$(2.87)</td>
<td>$(1.17)</td>
</tr>
<tr>
<td>Prior</td>
<td>$(3.13)</td>
<td>$(2.51)</td>
<td>$(2.13)</td>
<td>$(0.50)</td>
</tr>
</tbody>
</table>

Jeffrey Osborne  
646 562 1391  
jeffrey.osborne@cowen.com

---

Technology, Media & Telecom

**VeriSign**

Solid 3Q Results; Mgmt Confident Regarding NTIA Contract

**THE COWEN INSIGHT**

In the 3Q, VRSN added 2m net domain names (.com/.net) that were comfortably above the high end of the guided range. Mgmt also guided to in line 4Q net adds levels, and once again raised its unit growth for the full year. As well, VRSN struck a confident tone re: its contract renewal discussions with the NTIA. Valuation isn't cheap, but we have a positive bias on the shares.

**MARKET PERFORM (2)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NASDAQ: VRSN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$155.00</td>
</tr>
<tr>
<td>Price (10/25/2018)</td>
<td>$135.84</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$16,561.4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EPS $</th>
<th>2017A</th>
<th>2018E</th>
<th>2019E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$3.96</td>
<td>$4.69</td>
<td>$5.32</td>
</tr>
<tr>
<td>Consensus</td>
<td>$4.00</td>
<td>$4.60</td>
<td>$5.19</td>
</tr>
</tbody>
</table>

Gregg Moskowitz, CFA  
646 562 1390  
gregg.moskowitz@cowen.com

---
Capital Goods/Industrials

Visteon Corporation

Near Term Challenges But Optimism on 2020 and Beyond; Bookings Remain Strong

OUTPERFORM (1)

THE COWEN INSIGHT
VC reset guidance below the recently revised Street expectations given lower production volumes in all regions. Bookings activity remains robust, with $1.6bn in 3Q and $5.4bn YTD, giving us confidence in a revenue ramp in 2020 and beyond given design wins for new platforms. Reiterate Outperform and trim PT to $125 on lower estimates and multiple.

Jeffrey Osborne
646 562 1391
jeffrey.osborne@cowen.com

Technology, Media & Telecom

Western Digital Corporation

Who'll Stop The Rain?

MARKET PERFORM (2)

THE COWEN INSIGHT
WDC did a decent job at resetting the bar, but elevated NAND and HDD inventory amid a challenging demand backdrop threatens revenue, GM and FCF stability for the next few quarters. See upcoming analyst day in December crucial to assuaging investor concerns. Target to $60.

Karl Ackerman, CFA
415 646 7219
karl.ackerman@cowen.com

Macro Commentary Today

WRG Macro Commentary

WRG Washington Strategy

Gimme Shelter: Washington Weekly

THE COWEN INSIGHT
Week Four of Khashoggi Saga, Caravan and now 800 troops to southern border, Fake Middle Class Tax Cut, Senate refers Michael Avenatti to FBI for criminal probe, pipe bombs mailed to high-profile Democrats, drug pricing plan, new U.S. demands on China for G20 talk, Trump-Putin meeting next month in Paris, Opioids bill signed, 11 days to the midterms.

Chris Krueger
202 868 5307
chris.krueger@cowen.com
Upcoming Conferences

POST-ELECTION POW-WOW
November 12-13, 2018
Washington, D.C.

8TH ANNUAL ENERGY & NATURAL RESOURCES CONFERENCE
December 4-5, 2018
New York, NY

5TH ANNUAL NETWORKING AND CYBERSECURITY SUMMIT
December 11-12, 2018
New York, NY
<table>
<thead>
<tr>
<th>Points Of Contact</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Product Management</strong></td>
<td><strong>Trading Desk</strong></td>
</tr>
<tr>
<td>Drew Payne</td>
<td>New York</td>
</tr>
<tr>
<td>Product Manager</td>
<td>646 562 1500</td>
</tr>
<tr>
<td>Alexander Katzman</td>
<td></td>
</tr>
<tr>
<td>646 562 1597</td>
<td>Boston</td>
</tr>
<tr>
<td>Kyle Flynn</td>
<td>617.946.3890</td>
</tr>
<tr>
<td>646 562 1542</td>
<td></td>
</tr>
</tbody>
</table>
Important Disclosures and Information Relating to Cowen Washington Research Group

Cowen Washington Research Group produces commentaries on political, economic or market conditions. Commentaries produced by Cowen Washington Research Group are not intended as research reports as defined in FINRA Rule 2241 Research Analysts and Research Reports or FINRA Rule 2242 Debt Research Analysts and Debt Research Reports. Sections of this report noted as authored by Cowen Washington Research Group have not been prepared, are not intended, and should not be interpreted as a research report or investment recommendation regarding securities of any company. Investors should not consider purchasing or selling securities based upon any information contained in sections of the report denoted as authored by Cowen Washington Research Group.

Analyst Certification

Each author of this research report hereby certifies that (i) the views expressed in the research report accurately reflect his or her personal views about any and all of the subject securities or issuers, and (ii) no part of his or her compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views expressed in this report.

Important Disclosures

This report constitutes a compendium report (covers six or more subject companies). As such, Cowen and Company, LLC chooses to provide specific disclosures for the companies mentioned by reference. To access current disclosures for all companies in this report, clients should refer to https://cowen.bluematrix.com/sellside/Disclosures.action or contact your Cowen and Company, LLC representative for additional information.

Cowen and Company, LLC compensates research analysts for activities and services intended to benefit the firm’s investor clients. Individual compensation determinations for research analysts, including the author(s) of this report, are based on a variety of factors, including the overall profitability of the firm and the total revenue derived from all sources, including revenues from investment banking, sales and trading or principal trading revenues. Cowen and Company, LLC does not compensate research analysts based on specific investment banking transactions or specific sales and trading or principal trading revenues.

Disclaimer

Our research reports are simultaneously available to all clients on our client website. Research reports are for our clients only. Not all research reports are disseminated, e-mailed or made available to third-party aggregators. Cowen and Company, LLC is not responsible for the redistribution of research by third party aggregators. Selected research reports are available in printed form in addition to an electronic form. All published research reports can be obtained on the firm’s client website, https://cowenlibrary.bluematrix.com/client/library.jsp.

The information, opinions, estimates and forecasts are as of the date of this report and subject to change without prior notification. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Research reports are published at irregular intervals as appropriate in the analyst’s judgement.

Further information on subject securities may be obtained from our offices. This research report is published solely for information purposes, and is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. Other than disclosures relating to Cowen and Company, LLC, the information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete statement or summary of the available data. Any opinions expressed herein are statements of our judgment on this date and are subject to change without notice. The opinions and recommendations herein do not take into account individual client circumstances, objectives or needs and are not intended as recommendations of investment strategy. The recipients of this report must make their own independent decisions regarding any securities subject to this research report. In some cases, securities and other financial instruments may be difficult to value or sell and reliable information about the value or risks related to the security or financial instrument may be difficult to obtain. To the extent that this report discusses any legal proceedings or issues, it has not been prepared to express or intended to express any legal conclusion, opinion or advice. Our salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed in our research. Our principal trading area and investing businesses may make investment decisions that are inconsistent with recommendations or views expressed in our research. Cowen and Company, LLC maintains physical, electronic and procedural information barriers to address the flow of information between and among departments within Cowen and Company, LLC in order to prevent and avoid conflicts of interest with respect to analyst recommendations.

For important disclosures regarding the companies that are the subject of this research report, please contact Compliance Department, Cowen and Company, LLC, 599 Lexington Avenue, 20th Floor, New York, NY 10022. In addition, the same important disclosures, with the exception of the valuation methods and risks, are available on the Firm’s disclosure website at https://cowen.bluematrix.com/sellside/Disclosures.action.

Equity Research Price Targets: Cowen and Company, LLC assigns price targets on all companies covered in equity research unless noted otherwise. The equity research price target for an issuer’s stock represents the value that the analyst reasonably expects the stock to reach over a performance period of twelve months. Any price targets in equity securities in this report should be considered in the context of all previously published Cowen and Company, LLC equity research reports (including the disclosures in any such equity report or on the Firm’s disclosure website), which may or may not include equity research price targets, as well as developments relating to the issuer, its industry and the financial markets. For equity research price target valuation methodology and risks associated with the achievement of any given equity research price target, please see the analyst’s equity research report publishing such targets.

Cowen Credit Research and Trading: Due to the nature of the fixed income market, the issuers or debt securities of the issuers discussed in “Cowen Credit Research and Trading” research reports do not assign ratings and price targets and may not be continuously followed. Accordingly, investors must regard such branded reports as providing stand-alone analysis and reflecting the analyst’s opinion as of the date of the report and should not expect continuing analysis or additional reports relating to such issuers or debt securities of the issuers.

From time to time “Cowen Credit Research and Trading” research analysts provide investment recommendations on securities that are the subject of this report. These recommendations are intended only as of the time and date of publication and only within the parameters specified in each individual report. “Cowen Credit Research and Trading” investment recommendations are made strictly on a case-by-case basis, and no recommendation is provided as part of an overarching rating system or other set of consistently applied benchmarks. The views expressed in this report may differ from the views offered in the firm’s equity research reports prepared for our clients.

Notice to UK Investors: This publication is produced by Cowen and Company, LLC which is regulated in the United States by FINRA. It is to be communicated only to persons of a kind described in Articles 19 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. It must not be further transmitted to any other person without our consent.

Notice to European Union Investors: Individuals producing recommendations are required to obtain certain licenses by the Financial Regulatory Authority (FINRA). You can review the author’s current licensing status and history, employment history and, if any, reported regulatory, customer dispute, criminal and other matters via “Brokercheck by FINRA” at http://
An individual’s licensing status with FINRA should not be construed as an endorsement by FINRA. General biographical information is also available for each Research Analyst at www.cowen.com.

Additionally, the complete preceding 12-month recommendations history related to recommendation in this research report is available at https://cowen.bluematrix.com/sellside/Disclosures.action

The recommendation contained in this report was produced at October 26, 2018, 07:00 ET. and disseminated at October 26, 2018, 07:00 ET.

Copyright, User Agreement and other general information related to this report

© 2018 Cowen and Company, LLC. All rights reserved. Member NYSE, FINRA and SIPC. This research report is prepared for the exclusive use of Cowen clients and may not be reproduced, displayed, modified, distributed, transmitted or disclosed, in whole or in part, or in any form or manner, to others outside your organization without the express prior written consent of Cowen. Cowen research reports are distributed simultaneously to all clients eligible to receive such research reports. Any unauthorized use or disclosure is prohibited. Receipt and/or review of this research constitutes your agreement not to reproduce, display, modify, distribute, transmit, or disclose to others outside your organization. All Cowen trademarks displayed in this report are owned by Cowen and may not be used without its prior written consent.

Cowen and Company, LLC. New York 646 562 1010 Boston 617 946 3700 San Francisco 415 646 7200 Chicago 312 577 2240 Cleveland 440 331 3531 Atlanta 866 544 7009
Stamford 646 616 3000 Washington, D.C. 202 868 5300 London (affiliate) 44 207 071 7500

**COWEN AND COMPANY EQUITY RESEARCH RATING DEFINITIONS**

**Outperform (1):** The stock is expected to achieve a total positive return of at least 15% over the next 12 months

**Market Perform (2):** The stock is expected to have a total return that falls between the parameters of an Outperform and Underperform over the next 12 months

**Underperform (3):** Stock is expected to achieve a total negative return of at least 10% over the next 12 months

**Assumption:** The expected total return calculation includes anticipated dividend yield

**Cowen and Company Equity Research Rating Distribution**

<table>
<thead>
<tr>
<th>Rating</th>
<th>Count</th>
<th>Ratings Distribution</th>
<th>IB Services/Past 12 Months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buy (a)</td>
<td>472</td>
<td>63.44%</td>
<td>115</td>
</tr>
<tr>
<td>Hold (b)</td>
<td>266</td>
<td>35.75%</td>
<td>23</td>
</tr>
<tr>
<td>Sell (c)</td>
<td>6</td>
<td>0.81%</td>
<td>0</td>
</tr>
</tbody>
</table>

(a) Corresponds to “Outperform” rated stocks as defined in Cowen and Company, LLC’s equity research rating definitions. (b) Corresponds to “Market Perform” as defined in Cowen and Company, LLC’s equity research ratings definitions. (c) Corresponds to “Underperform” as defined in Cowen and Company, LLC’s equity research ratings definitions. Cowen and Company Equity Research Rating Distribution Table does not include any company for which the equity research rating is currently suspended or any debt security followed by Cowen Credit Research and Trading.

Note: “Buy”, “Hold” and “Sell” are not terms that Cowen and Company, LLC uses in its ratings system and should not be construed as investment options. Rather, these ratings terms are used illustratively to comply with FINRA regulation.
Reaching Cowen

Main U.S. Locations

<table>
<thead>
<tr>
<th>Location</th>
<th>Address</th>
<th>Phone Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>New York</td>
<td>599 Lexington Avenue, New York, NY 10022</td>
<td>646 562 1010, 800 221 5616</td>
</tr>
<tr>
<td>Atlanta</td>
<td>3399 Peachtree Road NE, Suite 417, Atlanta, GA 30326</td>
<td>866 544 7009</td>
</tr>
<tr>
<td>Boston</td>
<td>Two International Place, Boston, MA 02110</td>
<td>617 946 3700, 800 343 7068</td>
</tr>
<tr>
<td>Chicago</td>
<td>181 West Madison Street, Suite 3135, Chicago, IL 60602</td>
<td>312 577 2240</td>
</tr>
<tr>
<td>Cleveland</td>
<td>20006 Detroit Road, Suite 100, Rocky River, OH 44116</td>
<td>440 331 3531</td>
</tr>
<tr>
<td>Stamford</td>
<td>262 Harbor Drive, Stamford, CT 06902</td>
<td>646 616 3000</td>
</tr>
<tr>
<td>San Francisco</td>
<td>One Maritime Plaza, 9th Floor, San Francisco, CA 94111</td>
<td>415 646 7200, 800 858 9316</td>
</tr>
<tr>
<td>Washington, D.C.</td>
<td>2900 K Street, NW, Suite 520, Washington, DC 20007</td>
<td>202 868 5300</td>
</tr>
</tbody>
</table>

International Location

Cowen International Limited

London
1 Snowden Street - 11th Floor
London EC2A 2DQ
United Kingdom
44 20 7071 7500